Arix Bioscience Leads $65M Funding Round For Iterum
A recently established unit of health care and life science company Arix Group that is focused on the development of an oral and intravenous antibiotic to treat Gram-negative multi-drug resistant infections...To view the full article, register now.
Already a subscriber? Click here to view full article